share_log

Roth MKM Reiterates Buy on Tenax Therapeutics, Maintains $6 Price Target

Benzinga ·  Nov 14, 2023 01:20

Roth MKM analyst Jonathan Aschoff reiterates Tenax Therapeutics (NASDAQ:TENX) with a Buy and maintains $6 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment